Viatris Inc. (VTRS) Tax Rate: 4.10%
Is Viatris Inc.’s tax rate high or low?
Viatris Inc.'s tax rate of 4.10% is 40% above its 5-year average of 2.93%, around the middle of its 5-year range (-91.01%–73.04%).
251.93% above its 12-month average of 1.16%.
VTRS Tax Rate Chart
VTRS Average Tax Rate Chart
VTRS Current vs Average Tax Rate Chart
VTRS Tax Rate Metrics
TAX RATE
4.10%
TAX RATE AVG TTM
1.16%
TAX RATE AVG 3Y
25.37%
TAX RATE AVG 5Y
2.93%
TAX RATE AVG 10Y
-18.29%
TAX RATE AVG 15Y
9.07%
TAX RATE AVG 20Y
8.46%
CURRENT VS TTM AVG
+251.93%
CURRENT VS 3Y AVG
-83.84%
CURRENT VS 5Y AVG
+39.93%
CURRENT VS 10Y AVG
+122.41%
CURRENT VS 15Y AVG
-54.78%
CURRENT VS 20Y AVG
-51.53%
Viatris Inc. Tax Rate Formula & Definition
Tax rate measures income tax expense as a percentage of income before tax. It helps compare tax efficiency and identify unusual tax effects.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Viatris Inc. Tax Rate FAQ
- What is the tax rate for Viatris Inc. (VTRS)?
- The tax rate for VTRS stock is 4.10%.
- Is Viatris Inc.'s tax rate high or low?
- Viatris Inc.'s tax rate of 4.10% is 40% above its 5-year average of 2.93%, around the middle of its 5-year range (-91.01%–73.04%).
- What is the TTM average tax rate for Viatris Inc. (VTRS)?
- The TTM average tax rate for VTRS stock is 1.16%.
- What is the 3Y average tax rate for Viatris Inc. (VTRS)?
- The 3Y average tax rate for VTRS stock is 25.37%.
- What is the 5Y average tax rate for Viatris Inc. (VTRS)?
- The 5Y average tax rate for VTRS stock is 2.93%.
- What is the 10Y average tax rate for Viatris Inc. (VTRS)?
- The 10Y average tax rate for VTRS stock is -18.29%.
- What is the 15Y average tax rate for Viatris Inc. (VTRS)?
- The 15Y average tax rate for VTRS stock is 9.07%.
- What is the 20Y average tax rate for Viatris Inc. (VTRS)?
- The 20Y average tax rate for VTRS stock is 8.46%.
Viatris Inc. Tax Rate History
| DATE | TAX RATE |
|---|---|
| 2025-12-31 | 4.10% |
| 2024-12-31 | -1.77% |
| 2023-12-31 | 73.04% |
| 2022-12-31 | 26.11% |
| 2021-12-31 | -91.01% |
| 2020-12-31 | 7.11% |
| 2019-12-31 | 89.12% |
| 2018-12-30 | -18.13% |
| 2017-12-30 | 22.92% |
| 2016-12-30 | -294.41% |
| 2015-12-30 | 7.40% |
| 2014-12-30 | 4.25% |
| 2013-12-30 | 16.16% |
| 2012-12-31 | 20.04% |
| 2011-12-31 | 17.69% |
| 2010-12-31 | 2.92% |
| 2009-12-31 | -9.15% |
| 2008-12-31 | -179.65% |
| 2007-12-31 | -5.56% |
| 2006-03-31 | 32.80% |
| 2005-03-31 | 34.80% |
| 2004-03-31 | 34.72% |
Related Metrics
About Viatris Inc.
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Scott Andrew Smith